CD274 and cancer: The use of blocking mAbs against the immune checkpoints CTLA-4, programmed cell death protein 1 (PD-1), and PD-1 ligand 1 (PD-L1) has demonstrated significant clinical success in patients with a variety of cancers (74–76).